Syndax’s Axatilimab Misses Primary Endpoint in Phase 2 IPF Trial, Company Ends Development

Syndax’s MAXPIRe Phase 2 trial of axatilimab in IPF missed its primary FVC endpoint. Well tolerated; no further development in IPF planned.